Cardiovascular Prevention — Cardiology Guide

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Prevention is a closed-loop treatment plan. Identify the phenotype → use the correct risk estimate → personalize → set numeric targets → prescribe enough therapy → date the monitoring plan. A calculator informs a decision; it never cancels a direct indication.

Sort first: the score is decision-specific

do not use one bypass bucket

Decision	Score not needed when…	Action
Secondary prevention	Clinical atherosclerotic ASCVD: MI/ACS, coronary revascularization, atherosclerotic ischemic stroke/TIA, symptomatic PAD, or other clinically established atherosclerotic arterial disease. Incidental aortic calcium alone is not a clinical event.	Use phenotype-specific ASCVD stack (P.17); do not relabel hemorrhagic/cardioembolic stroke, SCAD, vasospasm, or isolated type-2 MI as conventional ASCVD.
LDL-C	LDL ≥190 mg/dL / probable FH; established ASCVD; or guideline-defined diabetes, CKD stage ≥3, or HIV treatment pathway.	Treat the condition. PREVENT may refine intensity in eligible primary prevention, but is not a residual-risk calculator for known CVD.
Stage-1 BP	Known CVD/prior stroke, diabetes, or CKD; or average BP ≥140/90.	For otherwise eligible BP 130–139/80–89, use 10-y PREVENT-CVD; ≥7.5% supports medication now.
Primary prevention	No direct indication, age 30–79 and no known CVD. For the lipid pathway, LDL-C 70–189 mg/dL and no known subclinical atherosclerosis.	Use PREVENT-ASCVD for lipids and PREVENT-CVD/HF for total CVD/HF decisions.

The one-visit close

five actions

A · IdentifyASCVD phenotype · CKM stage · severe LDL/FH · hypertension pattern · cancer exposure · pregnancy/frailty.

B · QuantifyValidated home BP · LDL/non-HDL · A1c · eGFR + UACR · tobacco · weight/waist · PREVENT result when valid.

C · PersonalizeFamily history · Lp(a) · apoB/TG · CAC only if uncertainty remains · reproductive/inflammatory/HIV context · access.

D · PrescribeNumeric BP/LDL goals · drug + dose · lifestyle prescription · safety labs · affordability/adherence solution.

E · DateFirst check, lab recheck, titration decision, and next appointment—not “follow up as needed.”

Leave this card now SBP >180 or DBP >120 with acute neurologic, cardiac, aortic, retinal, or renal injury; new focal deficit, exertional chest pressure, syncope, limb ischemia, or decompensated HF requires an emergency/diagnostic pathway.

One-line plan Risk lane ____ · CKM stage ____ · BP target ____ · LDL/non-HDL target ____ · therapy today ____ · labs ____ · next date ____

Commit the plan before sign-out

owner + date + escalation rule

Data ownerWho obtains the home BP, outside records, lipid response, eGFR/UACR, or sleep study—and by what date?

Therapy ownerName the drug, dose, access route, lifestyle prescription, and who resolves intolerance or denial.

Safety ownerList baseline/first-check labs, sick-day or procedure holds, pregnancy plan, and symptoms that trigger a call.

Escalation ownerPre-write the next step if BP, LDL, weight complication, adherence, or safety result remains outside target.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

2026 operating system: pair PREVENT with CKM stage. PREVENT estimates 10-year ASCVD, HF, and total CVD risk at age 30–79 and 30-year risk at age 30–59 in adults without known CVD; CKM stage identifies the disease state and organ-protection pathway.

Minimum dataset

measure once · act repeatedly

PressureHome BPValidated upper-arm cuff; orthostatics when indicated.

AtherogenicLDL · non-HDLLp(a) once; apoB for discordance; TG phenotype.

Kidney · glucoseeGFR + UACRA1c/glucose; repeat abnormal albuminuria to establish chronicity.

Whole patientTobacco · waistSleep, activity, diet, medications, pregnancy, access, mood.

Choose the PREVENT output that answers the question

validated age 30–79 · no known CVD

Output	Use	Threshold / boundary
PREVENT-ASCVD	Primary-prevention lipid decisions.	10-y: low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%. In age 30–59 with 10-y <3%, statin is reasonable if LDL 160–189 or 30-y ASCVD ≥10%.
PREVENT-CVD	Stage-1 BP decision and total CVD framing.	At BP 130–139/80–89 without CVD/stroke, diabetes, or CKD: ≥7.5% supports medication now.
PREVENT-HF	CKM/HF risk; selective pre-HF biomarker/echo discussion.	In CKM stages 0–3, ≥5% can support selected natriuretic peptide/hs-troponin testing and echocardiography when indicated—not blanket screening.
Do not extrapolate	Known CVD, age outside 30–79, or inputs outside model range.	Use disease-specific guidance, clinical judgment, competing risk, frailty, and time-to-benefit.

CKM stage → protective layer

eGFR + UACR drive action

Stage 0	No CKM risk factors.	Preserve cardiovascular health; periodic rescreen.
Stage 1	Excess/dysfunctional adiposity or prediabetes only.	Treat weight complications early; prevent progression to multiple metabolic risks.
Stage 2	HTN, TG ≥150, metabolic syndrome, diabetes, or moderate/high-risk CKD.	Quantify CVD/HF risk; layer BP, lipid, glucose, kidney, and obesity therapy.
Stage 3	Subclinical CVD (e.g., CAC ≥100, plaque, ABI <0.9, pre-HF), PREVENT-CVD ≥20%, or very-high-risk CKD.	High-intensity prevention; evaluate subclinical disease only when it changes management.
Stage 4	Clinical CVD plus a CKM risk factor or CKD.	Secondary prevention + organ-protection stack; 4a no kidney failure / 4b kidney failure.

Phenotype	Add to the foundation	Safety / boundary
Albuminuric CKD + HTN	Max tolerated ACEi or ARB; BP goal generally <130/80.	Check K/creatinine after start/titration; never ACEi + ARB.
CKD ± T2D	SGLT2 inhibitor at eGFR ≥20 for T2D+CKD; without diabetes, strong indication with UACR ≥200 mg/g or HF, with broader CKD use by phenotype.	Usually continue below eGFR 20 until KRT if tolerated. A modest initial eGFR dip is expected. Evaluate a fall >30%, volume loss or intercurrent illness rather than accepting it automatically.
T2D + ASCVD/high risk	SGLT2 inhibitor and/or GLP-1 receptor agonist with proven CV benefit, independent of A1c; combination may be considered.	Match the agent and enrolled phenotype; class labels are not interchangeable.
T2D + albuminuric CKD	ACEi/ARB + SGLT2 inhibitor; add finerenone if eGFR ≥25, K normal, and UACR ≥30 despite max tolerated RAAS therapy.	K/eGFR baseline and ~4 weeks; hold/adjust by label and interactions.
HF across EF	SGLT2 inhibitor unless contraindicated; add phenotype-specific HF therapy.	Do not prescribe as generic “post-MI prevention” without HF/CKD/diabetes indication.
CKM 2–3 + T2D	At PREVENT-CVD ≥7.5%, favor SGLT2 for CKD/pre-HF and GLP-1 for class II+ obesity, marked hyperglycemia, or MASLD.	Weight/glucose change alone is not proof of MACE benefit for every agent.

SGLT2 · beforeeGFR, volume/BP, DKA/insulin-deficiency history, genital-infection risk, diuretic burden.

Hold3 d before surgery/fasting; 4 d for ertugliflozin; also acute illness, poor intake, dehydration.

WatchGI symptoms, tachypnea, malaise, ketones—even with normal glucose; mycotic infection and volume loss.

RestartClinically stable, eating/drinking normally, ketone concern resolved, kidney/volume status acceptable.

Kidney pair + cadence eGFR alone misses albuminuric risk; UACR alone misses filtration loss. Obtain both, confirm chronicity, and repeat at least annually in diabetes—more often with CKD, treatment change, progression risk, electrolyte vulnerability, or intercurrent illness.

Screen wisely CAC is a selective decision aid, not population screening. Do not routinely screen asymptomatic low-risk adults with ECG/stress imaging or carotid ultrasound. One-time AAA ultrasound: men 65–75 who ever smoked; selective use in never-smokers.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

2026 lipid reset: start earlier, treat for lifetime exposure, and pair the expected percentage reduction with absolute LDL-C and non-HDL-C goals. Use enough potency to close the gap.

Phenotype → initial intensity → goal

shared decision does not mean delay

Who	Start	LDL / non-HDL goal	Escalate when
LDL ≥190 or probable FH	High-intensity statin; consider combination from start.	≥50% reduction; <100/<130 if no HeFH/major risk/plaque; <70/<100 if HeFH, added risk, or calcification.	Goal/gap not closed; early lipid-specialist + cascade-screening pathway.
Age 30–59; 10-y <3%	Moderate statin is reasonable if LDL 160–189 or 30-y PREVENT-ASCVD ≥10%.	Track lifetime exposure and response.	Risk enhancers, high Lp(a), strong family history, or CAC if genuinely uncertain.
Borderline 3–<5%	LLT reasonable after discussion.	<100 / <130	Goal not met or risk-enhancer burden favors more intensity.
Intermediate 5–<10%	LLT recommended after discussion.	<100 / <130	Goal not met; usually moderate/high-intensity statin.
High ≥10%	High-intensity statin; combination if large gap.	<70 / <100	Add nonstatin promptly to goal.
Diabetes · CKD ≥3 · HIV	Age ≥40 generally enters direct treatment pathway; check interactions/phenotype.	Risk-category goal; higher-risk patients often <70.	Goal not met or subclinical/clinical disease raises risk.
Clinical ASCVD	High-intensity/max-tolerated statin ± early add-on.	<70 if not very high risk.	Any recurrence, major-event burden, or persistent gap.
Very-high-risk ASCVD	Maximal combination therapy.	<55 / <85	Do not wait through serial low-impact titrations.

Very-high-risk is not every ASCVD patient. The 2026 definition requires ≥2 major ASCVD events, or 1 major event plus ≥2 high-risk features. Major events: ACS within 12 months, prior MI other than recent ACS, ischemic stroke or symptomatic PAD. Features: age ≥65, prior CABG/PCI, current smoking, diabetes, HF, hypertension or LDL ≥100 despite maximal statin + ezetimibe. Count events and features explicitly.

Lp(a), apoB & familial hypercholesterolemia

measure what changes action

Marker	When / threshold	Action
Lp(a)	Measure once in every adult; ≥125 nmol/L or ≥50 mg/dL is a risk enhancer. Do not use a fixed mass↔molar conversion.	Intensify proven prevention, screen family when appropriate, and recognize very high burden (around ≥250 nmol/L). Do not infer event benefit from Lp(a) lowering alone. See the dated outcome-trial update on P.21.
apoB	Useful with high TG, diabetes/CKM, obesity, or discordance despite apparently acceptable LDL/non-HDL.	Reveals residual atherogenic-particle burden; use to refine intensity, not as an unsupported universal target.
Suspected FH	Persistent untreated LDL ≥190, premature ASCVD, tendon xanthoma, arcus before age 45, strong premature family history, or a pathogenic variant.	LDL ≥190 triggers treatment but does not by itself prove monogenic FH. Reconstruct baseline LDL, exclude acquired causes, then use the formal diagnosis/cascade pathway on P.4.

CAC only when the result can change the choice

graduated 2026 targets

CAC 0	May defer in selected uncertainty only—never to de-risk LDL ≥190/FH, diabetes after 40, current smoking, or strong premature family history. If therapy is deferred, consider repeat CAC in 3–7 years according to baseline risk. This is not a guarantee against events.
CAC 1–99 and <75th percentile	Subclinical atherosclerosis: ≥30% LDL reduction, LDL <100, non-HDL <130.
CAC ≥100 or ≥75th percentile	Prefer ≥50% LDL reduction; LDL <70, non-HDL <100.
CAC ≥300	≥50% reduction and LDL <70; LDL <55 is reasonable.
CAC ≥1,000	LDL <55, non-HDL <85. Moderate/severe incidental CAC on nongated CT supports the ≥50% / <70 pathway.

Track response with lipids, not serial calcium scans. Statins can increase plaque calcification while reducing risk. A rising CAC score alone is not treatment failure. Track absolute LDL, percentage reduction, adherence and symptoms.

Combine reductions, then measure the result

illustrative arithmetic

160 × 0.50 × 0.80 = 64 mg/dL
Illustration, not an individual response prediction. This is a 60% total reduction. Add-on percentages do not add. Choose therapy by the remaining absolute gap, then recheck lipids in 4–12 weeks.

Complete example shown.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Separate the treatment threshold from the diagnosis. LDL-C ≥190 mg/dL is severe hypercholesterolemia and a direct treatment lane, but monogenic familial hypercholesterolemia (FH) is a phenotype assembled from the best untreated LDL, pedigree, examination, premature ASCVD, and—when informative—genetics.

Recognize → reconstruct → exclude → classify

three-generation pedigree

1 · Confirm the phenotypeRepeat a fasting or nonfasting lipid panel when needed; retrieve the highest credible pre-treatment LDL-C. Record age, therapy and adherence at every value; do not simply score an on-treatment LDL.

2 · Build the pedigreeDocument three generations: LDL elevation, known variant, tendon xanthomas, and premature coronary, cerebral, or peripheral disease—men <55 and women <60 for DLCN.

3 · Examine and excludeLook for tendon xanthomas and corneal arcus before 45. Review nutrition, weight change, pregnancy and drugs; check thyroid, kidney/protein loss, cholestatic liver disease, and glycemia.

4 · Score, test, cascadeUse an adult clinical tool such as DLCN; genetic testing can confirm etiology and makes family testing precise, but a negative panel does not erase a convincing clinical diagnosis.

Dutch Lipid Clinic Network (DLCN) score

choose one highest item per domain

Domain	Finding	Points
Family history	First-degree relative (FDR) with premature vascular disease or LDL >95th percentile; or FDR with tendon xanthoma/arcus, or child <18 with LDL >95th percentile	1; or 2
Personal history	Premature coronary disease; or premature cerebral/peripheral vascular disease	2; or 1
Examination	Tendon xanthoma; or corneal arcus before age 45	6; or 4
Untreated LDL-C	mmol/L controls: ≥8.5; 6.5–8.4; 5.0–6.4; 4.0–4.9 (approximately ≥325; 251–325; 191–250; 155–190 mg/dL)	8; 5; 3; 1
DNA	Pathogenic/likely pathogenic or established functional variant in LDLR, APOB, or PCSK9	8

Definite >8Probable 6–8Possible 3–5Unlikely 0–2

Worked example: untreated LDL 268 = 5 points; MI in a 51-year-old man = 2; father with MI at 54 = 1. Total 8 = probable FH. A causative LDLR variant adds 8 and makes the score definite. Choose only the highest item in each domain; xanthelasma scores 0, and absent xanthomas do not exclude FH.

Simon Broome alternative (UK/NICE): use pretreatment or highest recorded on-treatment adult total cholesterol >290 or LDL-C >190 mg/dL, plus tendon xanthomas in the patient/first- or second-degree relative or a causative LDLR/APOB/PCSK9 variant = definite; plus premature family MI (<60 first-degree or <50 second-degree) or family total cholesterol >290 in an adult first-/second-degree relative / >260 in a child or sibling <16 = possible. There is no “probable” category—never blend tools.

Find acquired causes, HoFH, and phenocopies

cause changes the family plan

Look for	Focused check	Clue / action
Thyroid · kidney	TSH; creatinine/eGFR, urinalysis or UACR, serum albumin	Hypothyroidism, CKD, or nephrotic protein loss can markedly raise LDL.
Liver · metabolic	AST/ALT, alkaline phosphatase, bilirubin; glucose/A1c; pregnancy/menopause, ketosis or rapid weight change	Seek cholestasis, uncontrolled diabetes/insulin resistance, Cushing syndrome, anorexia, or pregnancy.
Drugs · diet	Saturated/trans-fat pattern; glucocorticoids, cyclosporine, high-dose thiazides, sex hormones, atypical antipsychotics	Treat or substitute the driver when safe, then reassess the residual phenotype.
HoFH red flags	Untreated LDL-C >400; xanthomas before 10; both parents with untreated LDL compatible with HeFH; childhood/adolescent CAD or aortic-root/valve/ostial coronary disease	Urgent lipid-specialist/genetic assessment; phenotype outranks a deceptively simple genotype label.
Phenocopy / polygenic	ABCG5/8 sitosterolemia; LIPA lysosomal-acid-lipase deficiency; CYP27A1 cerebrotendinous xanthomatosis when cataracts/diarrhea/neurologic clues accompany xanthomas but cholesterol is modest	Expand testing when atypical; LDLRAP1 can cause recessive FH. Variable LDL/TG + high apoB may suggest familial combined hyperlipidemia.

Core panelLDLR · APOB · PCSK9; add LDLRAP1 or phenocopy genes by phenotype. A negative panel does not exclude clinical FH; a VUS is not a positive diagnosis.

CascadeOffer first-degree relatives lipids plus the known familial P/LP variant—never a VUS—then extend outward. If no variant is found/testing is unavailable, use age-appropriate lipid cascade screening.

Children are differentRefer for a parental P/LP variant regardless of LDL; otherwise LDL >175, or >135 with grandparent premature ASCVD/parent high cholesterol. If child testing is unavailable, parental variant + LDL >115 supports clinical FH. Suspected HoFH/two affected parents/early xanthomas: test birth–2.

DocumentUntreated LDL ____ · DLCN ____ · secondary workup ____ · phenotype/genotype ____ · relatives notified ____

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

New July 2026 Enlicitide is now an FDA-approved once-daily oral PCSK9 inhibitor for adult hypercholesterolemia including HeFH; LDL lowering is established, but MACE reduction awaits CORALreef Outcomes.

Use the potency required by the gap

start · effect · recheck · avoid/hold

Agent / start	Typical LDL effect	Evidence / use	Monitor · avoid/hold
Atorvastatin 40–80 Rosuvastatin 20–40	≥50%	Outcomes foundation; maximize tolerated dose.	ALT baseline; CK only with symptoms/high risk. Review pregnancy and interactions.
Moderate statin	30–49%	Atorvastatin 10–20, rosuvastatin 5–10, pravastatin 40–80, pitavastatin 1–4 mg.	Use lower-interaction options deliberately; none is interaction-free.
Ezetimibe 10 mg/d	~18–25%	Oral, low cost, outcomes-proven add-on.	Few interactions; recheck lipids 4–12 weeks.
Bempedoic acid 180 mg/d	~17–25%	Outcome benefit in statin-intolerant ASCVD/high-risk patients.	Uric acid/gout, tendon symptoms, cholelithiasis; check interactions.
PCSK9 monoclonal antibody	~50–60%	Evolocumab/alirocumab: hard-outcome benefit; close large gaps quickly.	Injection/access burden; confirm response and adherence.
Inclisiran	~50%	Day 0, 3 months, then q6 months; surrogate LDL evidence.	Outcome trials pending; do not claim MACE benefit yet.
Enlicitide	~56–59% at 24 weeks in approval trials	First oral PCSK9 inhibitor; daily alternative for eligible adults.	Approved on LDL lowering; outcomes pending. Follow label, interactions, adherence.

Statin-associated symptoms: preserve proven therapy

diagnose before declaring intolerance

1 · CharacterizeTiming, symmetry, proximal weakness, exercise; medication/supplement interactions, TSH, vitamin D only when clinically indicated.

2 · Safety exitSevere weakness, dark urine, marked CK elevation, renal injury, or objective liver injury → stop and evaluate urgently.

3 · Dechallenge / rechallengeAfter symptoms resolve, try lower dose, different statin, or alternate-day long-half-life statin; document response.

4 · CombineAny tolerated statin + ezetimibe/bempedoic acid/PCSK9-directed therapy usually beats abandoning statins and missing the LDL goal.

Triglycerides: separate MACE from pancreatitis

phenotype before product

TG	Do now	Drug boundary
150–499	Address alcohol, glycemia, weight, diet, hypothyroidism, kidney/liver disease and drugs; optimize statin by ASCVD risk.	Icosapent ethyl 2 g BID: US risk-reduction label requires TG ≥150 on maximal tolerated statin plus CVD, or diabetes + ≥2 additional CV risk factors. Monitor AF/flutter and bleeding.
500–999	Secondary causes, alcohol abstinence, dietary fat/carbohydrate strategy, diabetes control; consider fibrate or prescription omega-3.	Pancreatitis pathway. Olezarsen is labeled from TG ≥500: 50 mg SC monthly, increasing to 80 mg if tolerated and more lowering is needed. Review liver tests, hypersensitivity and access.
≥1,000	Chylomicronemia pathway: very-low-fat diet, urgent secondary-cause control, specialist evaluation; assess pancreatitis symptoms.	Urgent specialist pathway if symptoms or persistent severe elevation. Olezarsen eligibility begins at TG ≥500, not only ≥1,000. For familial chylomicronemia syndrome the labeled dose is 80 mg monthly.

Evidence + monitoring Statins, ezetimibe, bempedoic acid, and PCSK9 mAbs have outcomes evidence in defined populations. Inclisiran and enlicitide have powerful LDL-lowering evidence while dedicated outcomes trials remain pending. Baseline lipids + ALT; repeat lipids 4–12 weeks after start/change, then every 3–12 months by stability and adherence.

Document intolerance so treatment can continue

symptom story + response + replacement

ExposureDrug, dose, start/change date, interacting medicines, exercise/illness context, and prior tolerated statin.

PhenotypeLocation, symmetry, timing, weakness, CK/renal/liver findings when indicated, and competing cause.

CausalityResponse to dechallenge, time to resolution, rechallenge agent/dose, and whether symptoms recur.

Replacement planMaximally tolerated statin exposure + nonstatin combination, expected LDL effect, recheck date, and access plan.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Measure first, then treat. Confirm persistent hypertension with standardized office technique plus validated upper-arm home BP or ambulatory monitoring. Usual treatment goal is <130/80, individualized for orthostasis, frailty, pregnancy, and competing illness.

Home BP protocol

average, not the single highest value

PrepareNo nicotine, caffeine, or exercise for 30 minutes; empty bladder; sit quietly 5 minutes.

PositionBack supported, feet flat, legs uncrossed, arm supported at heart level, correct cuff on bare skin.

SampleTwo readings 1 minute apart morning and evening for ≥3, preferably 7, days; average all valid readings. If a validated analysis plan discards day 1, document it.

ValidateCompare device with clinic equipment; cuffless watches are not a diagnostic substitute.

Category → threshold → timing

2025 ACC/AHA pathway

Average BP	Category	Action
<120 and <80	Normal	Maintain cardiovascular health; reassess at least yearly.
120–129 and <80	Elevated	Lifestyle; reassess in 3–6 months.
130–139 or 80–89	Stage 1	Drug now for CVD/prior stroke, diabetes, CKD, or 10-y PREVENT-CVD ≥7.5%; otherwise lifestyle 3–6 months, then medicate if still ≥130/80.
≥140 or ≥90	Stage 2	Start 2 complementary first-line drugs, preferably a single-pill combination; review in ~1 month.
SBP >180 or DBP >120	Severe	Repeat correctly. Acute target-organ injury → emergency. No acute injury → prompt same-day/rapid evaluation and oral adjustment; do not crash BP.

Intensive SBP: translate the evidence carefully

standardized measurement

Target<130/80 for most treated adults. In selected high-CV/kidney-risk patients, a standardized SBP target near <120 may be reasonable if tolerated.

Evidence expansionSPRINT excluded diabetes/prior stroke; BPROAD and ESPRIT extend intensive-treatment evidence to diabetes and broader high-risk groups.

MonitorStanding BP, falls/syncope, Na/K/creatinine, volume status, cognition/function, and home values after each intensification.

IndividualizePregnancy, symptomatic orthostasis, frailty, limited life expectancy, autonomic dysfunction, or very low DBP with ischemic symptoms.

White coat / masked Out-of-office BP separates these phenotypes. Do not escalate white-coat hypertension from office values alone; do not dismiss high home/ambulatory BP because clinic BP is normal.

Out-of-office pattern → next move

confirm the phenotype

Office + home high	Sustained hypertension: verify technique/adherence, quantify target-organ risk, and treat to the individualized goal.
Office high · home normal	Possible white-coat effect: validate device/technique and use ambulatory monitoring when uncertainty changes treatment.
Office normal · home high	Possible masked hypertension: confirm with structured home/ambulatory data; do not dismiss the out-of-office burden.
Large variability	Check timing, missed doses, pain/anxiety, alcohol, OSA, autonomic/volume shifts, interacting drugs, and measurement error before adding therapy.

StartWrite the numeric target, home protocol, medication plan, and first safety check together.

RecheckBring cuff + log; compare achieved versus expected response, standing symptoms, adherence, and labs.

IntensifyPrefer complementary, long-acting agents and single-pill combinations when the confirmed average remains high.

Do not chaseA single peak, pain reading, unvalidated wearable, or asymptomatic low office value without context.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

One complementary combination beats serial monotherapy. For stage 2, begin an ACEi/ARB + long-acting DHP-CCB or thiazide-like diuretic unless a phenotype dictates otherwise; simplify to a single pill when possible.

Drug grid

start · prefer · recheck · avoid

Class / start	Prefer	First check	Avoid / caution
Losartan 50 mg Lisinopril 10 mg	Albuminuric CKD, diabetes, CAD/HF.	K + creatinine in ~1–2 weeks if high risk, no later than 2–4 weeks.	Pregnancy; ACEi + ARB; hyperkalemia/AKI.
Amlodipine 5 mg	Potent, once daily; useful with many oncology agents.	BP, edema in ~2–4 weeks.	Edema; check interactions before non-DHP CCB.
Chlorthalidone 12.5 mg Indapamide 1.25 mg	Outcome-proven volume/BP control; still useful in advanced CKD with monitoring.	Na/K/creatinine, volume in 1–2 weeks.	Hyponatremia, gout, volume depletion.
Spironolactone 12.5–25 mg	Preferred 4th drug in confirmed resistant HTN.	K within 1 week of starting or titrating, then regularly. Check renal function and more often with CKD/interactions.	Hyperkalemia, advanced CKD, endocrine adverse effects.
β-blocker	CAD/angina, HFrEF, arrhythmia, aortic disease.	Pulse, BP, symptoms.	Not routine first-line without a compelling indication.

Confirmed resistant hypertension

definition before escalation

DefineUncontrolled on 3 complementary maximally tolerated drugs (normally ACEi/ARB + long-acting DHP-CCB + appropriate diuretic), or controlled on ≥4.

Exclude pseudo-resistanceTechnique, white-coat effect, missed doses, undertitration, inadequate diuresis, high sodium/alcohol, NSAIDs, stimulants, OCPs, steroids.

Screen causesPrimary aldosteronism, OSA, CKD/renovascular disease, thyroid disease; pheochromocytoma/Cushing only with clues. Interpret ARR around interfering medications. Correct hypokalemia before interpreting a negative screen. Use a safe minimal- or no-withdrawal strategy when needed.

LayerOptimize diuretic → spironolactone when safe → specialist-directed alternatives/device evaluation.

What changed

new does not mean event-proven

Primary aldosteronism · 2025Endocrine Society conditionally suggests aldosterone/renin screening in all hypertension when feasible—not only hypokalemia/resistance.

Baxdrostat · FDA 2026Add-on for inadequately controlled adult HTN; usual 2 mg daily (1 mg if higher K/Na risk). Monitor K, Na, eGFR; initiation below eGFR 45 is not established. BP lowering proven; CV-event reduction is not.

Aprocitentan12.5 mg daily add-on for uncontrolled HTN; edema/fluid retention, anemia, hepatotoxicity precautions, and boxed pregnancy warning.

Renal denervationCan lower BP in selected resistant/uncontrolled patients at expert centers; hard-event prevention remains unproven.

Secondary cause: clue → focused action

screen broadly; test selectively

Primary aldosteronism	Hypertension itself now supports feasible aldosterone/renin screening; prioritize resistant HTN, hypokalemia, adrenal lesion, OSA, or early/familial disease. Interpret around medications and potassium.
OSA	Snoring, witnessed apnea, sleepiness, AF, obesity, resistant/nocturnal HTN → diagnostic sleep pathway; questionnaire alone does not diagnose.
Kidney / renovascular	eGFR, UACR, urinalysis and trajectory first; abrupt onset/worsening, asymmetric kidneys, flash pulmonary edema, or creatinine rise may justify targeted imaging.
Endocrine / aortic	TSH when indicated; metanephrines or cortisol only with clinical clues; compare arm/leg pulses and evaluate coarctation in the right phenotype.
Drug / substance	NSAIDs, stimulants, decongestants, OCPs, steroids, calcineurin/mTOR agents, alcohol, nicotine, licorice, supplements, and missed/short-acting doses.

START · RISK · LIPIDS · BP · OBESITY + OSA · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Obesity is a chronic, relapsing disease and a cardiovascular treatment target. Treat complications, function, and patient goals - not BMI alone. Lifestyle, medication, devices, and surgery are complementary; do not require serial "failure" before offering effective therapy.

Phenotype before product

baseline packet

AdiposityBMI + waistDated height/weight, trajectory, prior loss/regain, body composition when useful.

ComplicationsCVD · HF · CKDBP, lipids, T2D/prediabetes, OSA, MASH, OA, PCOS/fertility.

DriversSleep · drugsEating pattern, mood/ED risk, alcohol, steroids/insulin/psychotropics, mobility.

FunctionMuscle · frailtyStrength, falls, sarcopenia, protein/nutrition risk, resistance-training access.

Before first dose and at every escalation

closed-loop safety

Screen	Pregnancy/plans; personal/family MTC or MEN2; prior serious reaction; severe gastroparesis; pancreatitis/gallbladder history; retinopathy; eating disorder/frailty; kidney/volume risk.	Reconcile all diabetes/weight products, insulin/SU, diuretics/BP drugs, oral contraception, narrow-index drugs, and statins with Foundayo.
Measure	Dated weight/BMI/waist, BP/orthostasis, pulse, A1c/glucose, eGFR when indicated; symptoms, intake, strength/function, OSA/HF/MASH target.	Contact at each dose step. Delay escalation or adjust treatment within the product's labeled maintenance options. Some products require discontinuation or a formulation switch if the maintenance dose is not tolerated.
Prevent hypoglycemia	GLP-1 therapy alone rarely causes clinically important hypoglycemia; insulin and sulfonylureas do.	Preemptively plan glucose monitoring and dose reduction; do not reflexively stop metformin/SGLT2 organ protection.
Treat GI effects	Smaller/lower-fat meals, stop when full, fluids/electrolytes, constipation plan; slow or pause titration.	Persistent vomiting, dehydration/AKI, severe continuous abdominal pain, jaundice, or obstruction symptoms → stop/evaluate, not “push through.”
Reproductive	Stop weight-loss drugs when pregnancy is recognized; stop semaglutide ≥2mo before planned pregnancy.	For oral contraceptive users, use a nonoral method or add a barrier for 4 weeks after starting or increasing tirzepatide, and for 30 days after starting or increasing orforglipron.

Procedure / anesthesia plan

risk-stratified, not automatic holds

Most patientsMay continue GLP-1/GIP therapy before elective surgery/endoscopy after prescriber-proceduralist-anesthesia review.

Higher gastric riskEscalation phase, high dose, weekly drug, active nausea/vomiting/dyspepsia/constipation/distention, gastroparesis, or another emptying disorder.

MitigateDefer elective care until escalation/symptoms resolve when feasible; liquid-only diet ≥24h, aspiration-aware anesthesia, selective gastric ultrasound.

If holdingOptimal interval is unknown. Older fallback: daily drug on procedure day, weekly drug 7d. Plan glycemia; evidence is insufficient that holding prevents aspiration.

Build a chronic-treatment roadmap

benefit, function, durability

1 · MatchChoose the modality by complication, labeled indication, desired magnitude, contraindications, prior response, access, and patient preference.

2 · ProtectPair adequate protein/energy intake with progressive resistance exercise; track strength, falls, frailty, and sarcopenia risk—not weight alone.

3 · De-escalate safelyAs weight/BP/glucose fall, review insulin/SU, diuretic and antihypertensive doses; prevent hypoglycemia, orthostasis, and volume injury.

4 · MaintainDefine effective dose, refill/coverage fallback, monitoring cadence, and the plan for interruption, surgery, pregnancy, or recurrent weight.

Response is multidimensional: weight/waist + complication response + function/strength + symptoms/quality of life + tolerability + adherence/access. A plateau is not automatic treatment failure.

START · RISK · LIPIDS · BP · OBESITY + OSA · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Label checks Oct 17, 2026 All U.S. obesity-labeled incretins: semaglutide (Wegovy injection/HD/tablets), tirzepatide (Zepbound), liraglutide (Saxenda), and oral nonpeptide orforglipron (Foundayo). Compare trials cautiously: populations, diabetes status, duration, and missing-data methods differ.

Obesity-labeled incretins

dose · anchor result · boundary

Product	Start → maintenance	Anchor weight result	Do not miss
Wegovy SC	0.25 weekly x4wk → 0.5 → 1 → 1.7 → 2.4. Weight: 1.7/2.4; after ≥4wk at 2.4, may go directly to 7.2.	2.4: -14.9% vs -2.4% at 68wk. 7.2: -18.8% vs -15.5% on 2.4 vs -3.9% at 72wk.	CV: 1.7/2.4. MASH: 2.4 recommended, 1.7 if not tolerated. HD dysesthesia 22%. No pediatric HD.
Wegovy tablets	1.5 daily d1-30 → 4 d31-60 → 9 d61-90 → 25 daily. Empty stomach, ≤4 oz water; wait ≥30 min.	-13.6% vs -2.4% at 64wk; no weight trial in T2D.	Adult weight + MACE labels; SELECT directly tested SC 2.4, not tablet 25.
Zepbound	2.5 weekly x4wk → 5; +2.5 no sooner than q4wk. Weight: 5/10/15. OSA: 10/15. Max 15.	No T2D: -15.0/-19.5/-20.9% vs -3.1% at 72wk.	Oral contraception backup x4wk after start/each escalation; no obesity MACE claim.
Oral 2026 Foundayo	0.8 daily ≥30d → 2.5 ≥30d → 5.5; may advance 9 → 14.5 → 17.2, each ≥30d. With/without food.	No T2D: -7.4/-8.3/-11.1% vs -2.1% at 72wk.	No MACE/OSA claim. Simvastatin max 20 mg; major CYP3A4/OATP interaction review.
Saxenda	0.6 daily wk1 → 1.2 → 1.8 → 2.4 → 3 mg wk5+. Stop adult if <4% loss at wk16.	-7.4% vs -3.0% at 56wk.	No Saxenda MACE claim; LEADER tested Victoza 1.8 in high-risk T2D.

Non-incretin and rare-disease options

outcomes unestablished unless stated

Phentermine/topiramate ER	3.75/23 x14d → 7.5/46; at 12wk, <3% → 11.25/69 x14d then 15/92; stop if <5% after 12wk and taper highest dose.	-7.8% to -9.8% vs -1.2% at 1y. Pregnancy contraindicated. Test before starting and monthly when pregnancy is possible, with effective contraception/REMS. Avoid glaucoma, hyperthyroidism and MAOI. Monitor HR, mood, cognition, bicarbonate and stones.
Naltrexone/bupropion ER	8/90: 1 AM → 1 BID → 2 AM/1 PM → 2 BID; stop if <5% after 12wk maintenance.	-5.4% vs -1.3%. Avoid uncontrolled HTN, seizure/eating disorder/withdrawal, opioids, MAOI; CYP2D6 interactions.
Orlistat	120 mg TID with fat-containing meal (Alli 60 mg OTC); multivitamin A/D/E/K ≥2h apart.	Modest (~3% placebo-corrected). GI urgency, malabsorption/cholestasis, oxalate nephropathy; warfarin/cyclosporine/levothyroxine review.
Short-term sympathomimetics	Phentermine, diethylpropion, benzphetamine, phendimetrazine are labeled only for a few weeks.	Avoid CVD/arrhythmia/uncontrolled HTN, hyperthyroid, glaucoma, pregnancy, MAOI. Not a chronic CV-prevention strategy.
Setmelanotide	Specialist/genetic pathway for POMC/PCSK1/LEPR deficiency, Bardet-Biedl syndrome, or labeled acquired hypothalamic obesity.	Not common polygenic obesity; monitor pigmentation/nevi, sexual effects, depression, adrenal/sodium issues.

Brand firewall: Ozempic/Rybelsus (semaglutide), Mounjaro (tirzepatide), Victoza/generic liraglutide, Trulicity, Byetta/Bydureon BCise, Adlyxin, Soliqua, and Xultophy are diabetes products - not obesity products. No dose-for-dose substitution and never combine incretins or same-molecule brands.

Durability, products & procedures

maintenance before rescue

Interruption / switch	Use product-specific missed-dose/restart instructions; after longer gaps, re-titrate for GI tolerance. Confirm new presentation and train. Do not improvise dose equivalence.	Plan access fallback before the last dose; document baseline BMI and on-treatment response.
Product integrity	Prefer FDA-approved product. Do not use “research” products or assume compounded semaglutide/tirzepatide is interchangeable; verify formulation, source, and current FDA shortage/enforcement status.	FDA requested removal of the GLP-1 suicidality warning in Jan 2026; Contrave/Imcivree retain product-specific warnings.
Metabolic surgery	Sleeve/RYGB and other procedures offer the most durable large loss for eligible patients; refer by complication/goal, not only after every drug fails.	Lifelong micronutrient, bone, muscle, hypoglycemia, alcohol, absorption, and surgical follow-up.
Device 2026 Gastric balloon	Allurion swallowable balloon is FDA-approved for short-term limited loss in age 22-65, BMI 30-40 after an unsuccessful program.	Not a GLP-1 substitute or CV-outcome therapy; endoscopy/surgery backup, contraindications, and coverage vary.

START · RISK · LIPIDS · BP · OBESITY + OSA · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Outcome claims belong to the tested molecule, dose, product, population, and endpoint. Weight loss, noninferiority to an active comparator, and biomarker change are not interchangeable with placebo-superior MACE reduction.

Match the highest-value indication

label ≠ class analogy

Dominant phenotype	Preferred evidence lane	Boundary
Established CVD + overweight/obesity	Wegovy 2.4 mg SC (1.7 if needed) or 25 mg tablet carries adult MACE-risk-reduction labeling; SELECT used SC 2.4 mg.	Wegovy HD 7.2 mg is a weight dose, not the CV-label dose.
Moderate-severe OSA + BMI ≥30	Zepbound 10 or 15 mg weekly is FDA-labeled; treat anatomy, sleepiness, hypoxemia, and PAP barriers in parallel.	Weight response never authorizes automatic PAP withdrawal; retest.
Obesity-related HFpEF	Semaglutide and tirzepatide improve health status/weight; SUMMIT reduced worsening-HF/CV-death composite.	Evidence is phenotype-specific; neither product has a general HF indication.
T2D + ASCVD/CKD	Choose the diabetes-labeled GLP-1/GIP product with matched CV/kidney evidence, then solve weight and glycemia together.	Diabetes and obesity brands/doses are not interchangeable.
Noncirrhotic MASH F2-F3	Wegovy injection has accelerated-approval labeling. Use 2.4 mg weekly, or 1.7 mg if 2.4 is not tolerated, with consideration of re-escalation. Coordinate hepatology and fibrosis follow-up.	Tablets and HD 7.2 mg do not carry this indication.
Large durable loss needed	Discuss metabolic surgery at BMI ≥35 regardless of comorbidity; consider BMI 30-34.9 with metabolic disease or inadequate nonsurgical response.	Shared choice, surgical risk, nutrition, bone/muscle, absorption, lifelong follow-up.

What is proven now

patient-important outcomes

Trial	Population / therapy	Result	Translation
SELECT	17,604 adults ≥45 years with BMI ≥27 and established CVD, without diabetes. Semaglutide 2.4 mg SC weekly.	MACE 6.5% vs 8.0%; HR 0.80.	Direct obesity-CV evidence; secondary prevention.
FLOW / SOUL	T2D + albuminuric CKD / high-risk ASCVD-CKD; semaglutide.	FLOW kidney/CV-death HR 0.76; SOUL MACE 12.0% vs 13.8%, HR 0.86.	Diabetes/CKD evidence, not generic obesity claims.
LEADER / REWIND	High-risk T2D; liraglutide 1.8 / dulaglutide 1.5.	MACE HR 0.87 / 0.88.	Victoza/Trulicity diabetes evidence; not Saxenda.
SURPASS-CVOT	13,299 randomized, 13,165 analyzed. T2D + ASCVD. Tirzepatide vs dulaglutide 1.5 mg weekly.	MACE HR 0.92 (95.3% CI 0.83–1.01).	Noninferior, not superior, to dulaglutide. Mounjaro gained a T2D/high-CV-risk MACE label in Aug 2026. Zepbound has no obesity MACE claim.
SUMMIT	HFpEF + BMI ≥30; tirzepatide vs placebo.	CV death/worsening HF 9.9% vs 15.3%; HR 0.62.	Driven by worsening HF; no general HF label.
SURMOUNT-OSA	467 in the FDA label's two studies. Moderate-severe OSA + obesity. Tirzepatide 10/15 mg weekly.	AHI difference -20.0 / -23.8 events/h; remission/mild nonsymptomatic 42.2% / 50.2%.	FDA OSA indication; trials did not define PAP stopping.

Outcome pipeline

registry checked Oct 17, 2026

Trial / status	Agent	Question	Primary completion
SURMOUNT-MMONCT05556512 · active, not recruiting	Tirzepatide; N=15,374	Death, MI/stroke, revascularization, HF events.	Oct 2027
ATTAIN-OSANCT06649045 · completed	Orforglipron. N=712 actual	AHI at 52 weeks. No registry results posted and no OSA label.	Jul 2026 actual
REDEFINE 3NCT05669755 · active, not recruiting	CagriSema; N=7,101	MACE-3 and kidney outcomes.	Sep 2027
MARITIME-CV / TRIUMPHNCT07037433 / NCT06383390	MariTide N≈12,800 / retatrutide N≈10,000	MACE/HF/death; TRIUMPH also kidney composite.	Jun 2028 / Feb 2029
ATTAIN-OutcomesNCT07241390 · recruiting	Orforglipron; N≈7,140	MACE/HF/revascularization/death in ASCVD/CKD.	Aug 2031
SYNCHRONIZE-CVOTNCT06077864 · completed	Survodutide; N=5,531	Five-component CV/HF noninferiority; no posted results.	Jun 2026

Investigational means unavailable: do not prescribe "research" retatrutide, CagriSema, survodutide, or maridebart cafraglutide, and do not infer benefit from a passed registry date. See P.19–22 for the broader prevention trial ledger.

START · RISK · LIPIDS · BP · OBESITY + OSA · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Authorization is an indication-and-documentation task. Employer exclusions, preferred brands, step therapy, program duration, renewal thresholds, and pharmacy channels vary by plan/PBM; verify the live policy rather than copying another payer's rule.

One defensible PA packet

submit together

A · Product + indicationExact brand, formulation/presentation, dose, quantity, NDC when required; obesity vs MACE vs OSA vs T2D vs MASH diagnosis.

B · Objective phenotypeDated height/weight/BMI at initiation; prior MI/stroke/PAD records; PSG/AHI; HFpEF; serial BP + 2-drug list; eGFR/UACR; fibrosis staging.

C · Required historyStructured nutrition/activity dates, prior trajectory, plan-preferred therapies tried, intolerance/contraindication, and why this option matches outcome evidence.

D · Safety + duplicationPregnancy/MTC/MEN2/gastroparesis screen; no concurrent incretin/same molecule; titration, monitoring, and hypoglycemia plan.

E · RenewalWeight and percent change, achieved dose, adherence/possession, adverse effects, function and complication response; use the live plan continuation rule.

Medicare GLP-1 Bridge

live Jul 1, 2026-Dec 31, 2027

$50 / 28-30 d For eligible Part D beneficiaries, outside the Part D benefit: payment does not count toward the Part D deductible or TrOOP. Products: all Foundayo; all Wegovy injection/HD/tablets; Zepbound KwikPen only - not Zepbound single-dose pens/vials.

BMI lane	Required qualifying phenotype	Attest / route
BMI ≥35	No additional listed complication required.	Age ≥18; weight reduction/maintenance with ongoing structured nutrition and activity. New product switch requires new PA.
BMI ≥30	HFpEF; or SBP >140 or DBP >90 despite 2 antihypertensives; or CKD stage ≥3a.
BMI ≥27	Prediabetes; or prior MI; prior stroke; or symptomatic PAD.

Use ordinary Part D, not Bridge, for a coverable indication: T2D; Zepbound for moderate-severe OSA; Wegovy for established-CVD MACE reduction; or Wegovy injection for noncirrhotic MASH F2-F3. If nonformulary, use the Part D exception/appeal process. Broad Part D obesity coverage was not finalized for CY2026.

Denial → correction → appeal

quote the actual criterion

ReadCoverage exclusion vs missing data vs step therapy vs quantity/channel. Ask for policy version/date and the exact unmet clause.

CorrectResubmit missing baseline BMI, objective complication evidence, program dates, prior trials, dose/presentation, or no-duplication attestation.

AppealQuote label + plan criterion, attach matched evidence, request peer-to-peer/formulary exception, then external review where available; expedite only when criteria fit.

Preserve continuityConfirm stock, pharmacy channel and copay before each escalation; do not miscode obesity as diabetes or silently swap brand/formulation.

Set goals that change disease

not scale-only

TargetAgree on weight/waist and the complication to improve: BP, glycemia, OSA, HF symptoms, mobility, pain, fertility, or MASH.

Protect lean massProgressive resistance exercise 2-3 d/wk, adequate energy/protein, and frailty screening; individualize for CKD.

MeasureWeight, waist, BP/orthostasis, pulse, A1c/glucose, symptoms, intake, strength/function, adverse effects, medication possession.

Plan chronic careStopping commonly causes regain. Define maintenance, access fallback, pregnancy/procedure plan, and next titration date before starting.

START · RISK · LIPIDS · BP · OBESITY + OSA · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Screening is not diagnosis. Ask snoring, witnessed apnea, choking, nonrestorative sleep, sleepiness/drowsy driving, nocturia, morning headache, and insomnia in obesity, resistant HTN, AF, HF, CAD/stroke, pulmonary HTN, T2D, or bariatric candidates.

Test the right patient the right way

comprehensive sleep evaluation first

Test lane	Use	Next step
Polysomnography	Diagnostic standard; prefer with significant cardiorespiratory disease, neuromuscular weakness, awake/suspected hypoventilation, chronic opioids, prior stroke, or severe insomnia.	Split-night only when adequate diagnostic time and titration criteria are met.
Home sleep apnea test	Acceptable in an uncomplicated adult with signs/symptoms suggesting moderate-severe OSA.	Negative, inconclusive, or technically inadequate HSAT with ongoing suspicion → PSG; never diagnose from a questionnaire alone.
Interpret beyond AHI	Mild 5-14.9; moderate 15-29.9; severe ≥30 events/h. Review oxygen nadir/hypoxic burden, position/REM, central fraction, sleepiness, arrhythmia, and comorbidity.	AHI is one severity axis; safety-critical sleepiness and profound hypoxemia accelerate treatment.

Prescribe PAP as a supported intervention

device + interface + follow-up

InitiateHome APAP or in-lab titration for uncomplicated OSA; ongoing fixed CPAP or APAP. PAP is strongly recommended for excessive sleepiness.

Order completelyDiagnosis/test, CPAP/APAP mode and range/pressure, patient-chosen interface, heated humidification/tubing, supplies, education, remote-data access.

BPAPNot routine first-line OSA. Consider without backup when therapeutic CPAP pressure is ineffective or intolerable despite mask/pressure optimization; backup rate is not for pure OSA.

First 2-4 weeksReview hours and all-night use, residual AHI, leak, pressure, symptoms, side effects, and drowsy driving; intervene early, not at annual follow-up.

Medicare PAP coverage clock

payer threshold ≠ clinical goal

Qualify	AHI/RDI ≥15; or 5-14 with sleepiness, impaired cognition, mood disorder/insomnia, HTN, ischemic heart disease, or prior stroke.	Clinical evaluation before testing, valid ordered test and supplier education. Confirm Medicare scoring: hypopneas require ≥4% desaturation and RERAs are excluded.
Continue after 12wk	Practitioner re-evaluation no sooner than day 31 and no later than day 91: improved symptoms and objective PAP ≥4h/night on 70% of nights in one consecutive 30-d window during first 3mo.	The 4-h rule is a coverage threshold; prescribe use for the entire sleep period.
If initial trial fails	To requalify: in-person re-evaluation identifying failure cause plus repeat facility Type-I sleep test.	Do not wait for denial: schedule data review and re-evaluation when equipment is dispensed.

Cardiovascular boundary: PAP improves AHI, sleepiness, quality of life and modestly lowers BP, but SAVE (mean use 3.3 h/night) did not reduce events in nonsleepy established CVD: 17.0% vs 15.4%, HR 1.10. Treat OSA for its established benefits; do not promise universal MACE prevention.

Read the PAP download in sequence

use pattern before pressure change

1 · Exposure	Night-by-night use, all-night coverage, naps/travel, removal time, and whether symptoms occur during untreated sleep.
2 · Leak	Pattern and magnitude, mouth leak, interface/position, humidification, cushion/tubing age, and whether reported events are reliable.
3 · Events	Residual AHI trend and obstructive versus central pattern; relate to position, REM, pressure and symptoms—never treat one device number alone.
4 · Pressure	Median/upper pressure, range limits, flow limitation, aerophagia, awakenings, and whether fixed/APAP settings match the phenotype.
5 · Patient result	Sleepiness, drowsy driving, insomnia, BP, nocturia, partner report, oxygen concern, and ability to use PAP for the whole sleep period.
6 · Close loop	Change one or two correctable factors, name the owner, review remotely in days to weeks, and repeat objective testing when physiology or treatment changes.

START · RISK · LIPIDS · BP · OBESITY + OSA · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

"CPAP intolerant" is a problem list, not an endpoint. Identify interface, pressure, nasal, behavioral, positional, central-event, or access failure; optimize promptly, then choose an evidence-based alternative with objective follow-up.

Fix the common PAP failure modes

download before guessing

Problem	First moves	Escalate when
Leak / mouth leak	Observe fit and sleep position; refit size/style, replace cushion, nasal pillows vs nasal mask, chin support or full-face when indicated; avoid overtightening.	Persistent large leak, skin injury, dry mouth, or high residual AHI despite fit correction.
Dryness / congestion	Heated humidification/tube, saline, treat rhinitis, check oral leak and room humidity.	Structural nasal obstruction, recurrent epistaxis, or inability to use nasal interface.
Pressure / aerophagia	Ramp/expiratory relief, review APAP range and positional events; gradual desensitization while awake.	Persistent intolerance or ineffective CPAP after optimal settings/interface → titration/BPAP assessment.
Residual events	Confirm use, leak, event type, position and pressure; do not treat device-reported AHI in isolation.	Central events, hypoventilation/hypoxemia, symptoms, or AHI still high → sleep specialist and PSG/titration.
Behavior / access	Education, motivational/troubleshooting intervention, early telemonitoring, partner support; resolve cost/supplies and drowsy-driving safety.	Document attempted optimization before declaring intolerance or seeking device authorization.

Non-PAP and surgical pathways

verify response with sleep testing

Oral appliance	Custom, titratable mandibular advancement device by a qualified dentist when CPAP-intolerant or patient prefers alternate therapy; sleep physician oversight and follow-up testing.	Dental/TMJ/occlusal follow-up; CPAP usually lowers AHI/raises O₂ more.
Positional / adjuncts	Position-dependent OSA: structured positional device, nasal/tonsil therapy when relevant; verify efficacy. Avoid alcohol/sedatives and treat insomnia.	Adjunct or selected phenotype - not an untested replacement for effective PAP.
Weight pharmacotherapy	Zepbound 10/15 mg for moderate-severe OSA + obesity: AHI difference -20.0/-23.8 events/h at 52wk.	Trials did not establish when to stop PAP. Consider PSG/HSAT after a 10–20% weight change when it will change management. Confirm control before stopping PAP.
Surgical referral	Discuss sleep surgeon if BMI <40 and PAP intolerant/unaccepting; bariatric surgeon if BMI ≥35. PAP remains initial therapy even with major anatomy in most adults.	Nasal/tonsil/palatal/tongue-base surgery or MMA by anatomy; objective post-treatment test.

Document a complete nonimplant trial

optimization before abandonment

PAP exposureObjective use and all-night pattern, leak, residual events, pressure/interface changes, education/telemonitoring and the remaining failure mechanism.

Adjunct matchPosition, nasal obstruction, insomnia, sedatives/alcohol, weight trajectory, dentition/TMJ and whether the alternative treats the dominant anatomy.

SafetyDrowsy driving, profound hypoxemia, cardiopulmonary disease, central events or hypoventilation may make an unverified alternative unsafe.

VerificationSymptoms alone are insufficient: name the follow-up PSG/HSAT, oxygen assessment when indicated, adherence check and rescue plan.

Continue to implantable therapy on P.14 only after the PAP record, anatomy, objective severity, weight/medical options, payer criteria, interaction/MRI issues, and follow-up capacity are assembled.

START · RISK · LIPIDS · BP · OBESITY + OSA · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

An implant is a longitudinal therapy, not a one-time procedure. Match device label, airway/anatomy, PAP history, payer criteria, surgical risk and follow-up capacity; then activate, titrate and prove efficacy objectively.

Hypoglossal nerve stimulation: label vs coverage

cutting-edge devices

System	FDA lane	Access boundary
Inspire UAS	Adult ≥22, AHI 15-100, PAP failure/intolerance, no complete concentric palatal collapse; FDA BMI warning upper limit 40.	Medicare LCD example (L38310): age ≥22, BMI <35, PSG AHI 15-65 within 24mo, central/mixed <25%, documented optimized PAP failure/intolerance, and DISE without complete concentric collapse. Verify the applicable Medicare contractor, commercial policy and exact device. FDA approval does not establish coverage.
FDA 2025 Genio 2.1	Bilateral HNS; adult ≥22, AHI 15-65 after failure/intolerance/ineligibility for lifestyle, PAP/BPAP, oral appliance, and pharmacotherapy.
FDA Mar 2026 aura6000	Proximal HNS; adult moderate-severe OSA, AHI 15-65, after failure/intolerance/ineligibility for PAP, oral appliance, or pharmacotherapy.

Build the candidacy packet

select · authorize · coordinate

PhenotypeSeverity, central fraction, hypoxemia, BMI/weight trajectory, position, symptoms, cardiopulmonary disease and treatment goal.

AirwayNasal/tonsil/palatal/tongue-base anatomy, DISE pattern when required, dentition/TMJ, prior surgery and realistic modality match.

PAP recordObjective use/download, interface and pressure optimization, education/telemonitoring attempts, reason for failure and whether BPAP/titration was assessed.

CompatibilityMRI conditions, cardiac/other implants, surgical/anesthesia risk, occupation, travel, dexterity, charging/remote needs and payer channel.

Implant → activation → verified outcome

authorization is not success

Before implant	Confirm device-specific label and payer rule, DISE/anatomy, PAP record, comorbidity/surgical risk, MRI/interaction constraints, patient expectations and responsible teams.
Procedure / wound	Document implant model/components, operative issues, wound/nerve function, pain/infection plan, activity restrictions and urgent device/surgical symptoms.
Activation	Name activation date and clinician; teach remote/charging, sleep-time use, amplitude range and discomfort troubleshooting. A dormant implant provides no therapy.
Titration	Stepwise setting adjustment using adherence, symptoms, snoring/partner report and device data; address insomnia, position, weight and adjunctive anatomy rather than simply increasing output.
Efficacy test	Repeat PSG/HSAT at the appropriate interval; document AHI/hypoxemia, symptoms, BP/safety, nightly use and need for adjunct or rescue PAP.
Long term	Annual sleep/device follow-up, battery/component planning, MRI/other-procedure precautions, weight/anatomy changes, adverse effects and objective retesting when response changes.

Close the device loop: approval → implant → activation → titration → objective efficacy → durable nightly use. Keep PAP available when the implant/alternative does not adequately control OSA or hypoxemia.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Write lifestyle like a prescription: the specific behavior, dose, support, and follow-up. Then remove access barriers; advice a patient cannot afford or execute is not a completed intervention.

Core prescriptions

specific beats “do better”

Domain	Prescription	Safety / nuance
Food pattern	Mediterranean or DASH: vegetables, fruit, legumes, nuts, whole grains, fish; replace saturated fat with unsaturated fats; minimize refined starch, processed meat, and ultra-processed foods.	Culture, budget, dentition, allergies, eating disorder risk; dietitian when complexity is high.
Sodium / potassium	Aim sodium <1,500 mg/day when feasible or reduce ≥1,000 mg/day; use potassium-rich foods when safe.	Do not recommend potassium salt/substitution blindly in CKD, hyperkalemia, or RAAS/MRA therapy.
Movement	≥150 min/wk moderate or 75 vigorous aerobic + resistance ≥2 d/wk; start below capacity, break sitting every 30–60 min.	Use cardiac rehab/structured PAD exercise; pre-exercise evaluation only when symptoms/risk warrant.
Alcohol	Do not start for health; less is better. Ask quantity, pattern, and BP/TG/AF/sleep effects.	Abstinence with pregnancy, liver disease, addiction, severe TG, interactions, or patient preference.
Sleep	7–9 h for most adults; screen OSA with snoring, witnessed apnea, resistant HTN, AF, obesity, or sleepiness. Use the testing/PAP pathway on P.12.	CPAP improves symptoms/BP in appropriate OSA; troubleshoot PAP/nonimplant options on P.13 and implantable devices on P.14. Do not promise universal MACE reduction.

Nicotine + aspirin: close two common gaps

treat dependence · default no aspirin

Varenicline	Preferred single agent for many nonpregnant adults. Use a quit date or flexible start, adjust for renal function and monitor nausea, sleep and mood.	Ask cigarettes, vaping, cigars, smokeless tobacco, cannabis co-use and secondhand exposure; pair medication with counseling/quitline.
Combination NRT	Daily patch + gum/lozenge for breakthrough cravings; teach chew-and-park and dose by dependence.	Bupropion SR can help depression/weight concern; avoid seizure/eating disorder, abrupt alcohol/sedative withdrawal, or MAOI.

Aspirin primary prevention: default no. USPSTF: age 40–59 with ≥10% 10-y CVD risk, individualized net benefit; do not initiate at ≥60. ACC/AHA: selected age 40–70 at high ASCVD and low bleeding risk; avoid routine use >70 or with prior GI/intracranial bleeding, bleeding disorder, thrombocytopenia, anticoagulant/NSAID burden, uncontrolled HTN, CKD-related bleeding risk, frailty, or falls.

Six high-yield population modules

personalize without stereotyping

Pregnancy · preconception · postpartumTreat/titrate chronic HTN at 140/90. SBP ≥160 or DBP ≥110 persisting ≥15 minutes requires urgent obstetric treatment within 30–60 minutes. Review ACEi/ARB/MRA/statin/weight drugs. Most stop statins; specialist-plan rare HoFH/very-high-risk exceptions; do not breastfeed on a statin.

Female-specific enhancersPrior preeclampsia/gestational HTN or diabetes, preterm delivery, premature menopause, and PCOS reveal lifetime risk. Screen BP, lipids, glucose, kidney risk, tobacco, and weight deliberately.

Age <40Focus lifetime LDL/BP exposure, FH, diabetes/CKD, obesity, tobacco, pregnancy and family history. A low 10-y estimate should not create decades of therapeutic drift.

Age >75–79 · frailtyPREVENT is not validated beyond 79. Moderate statin may be reasonable with life expectancy ≥2.5 y; use function, cognition, falls, polypharmacy, absolute benefit and time-to-benefit.

HIVAge ≥40 enters the 2026 lipid pathway. REPRIEVE: pitavastatin 4 mg reduced MACE in ART-treated low/moderate-risk adults; check every ART–statin interaction and dose cap.

Inflammation · transplantRA/psoriasis/IBD, chronic infection, transplant, steroids, calcineurin/mTOR inhibitors alter risk and interactions. Coordinate immunosuppression; do not treat race as biology or use outdated race correction.

Reproductive safety + equity

confirm the label · design around the patient

Avoid / stop before or during pregnancy	Often used when treatment is needed	Do not miss
ACEi, ARB, direct renin inhibitor, mineralocorticoid antagonists; anti-obesity drugs; most pause statins unless a specialist-managed very-high-risk exception.	Labetalol, long-acting nifedipine, methyldopa; hydralazine for selected acute settings—follow obstetric protocol.	Preeclampsia prevention: aspirin 81 mg after 12 weeks, ideally before 16, for guideline-defined risk. After a hypertensive pregnancy, arrange BP assessment within 7–10 days postpartum, or within 72 hours after severe HTN. Headache, visual change, dyspnea, chest/RUQ pain, seizure or severe BP needs urgent assessment.

AskCan the patient obtain/store/take the drug, use the cuff, read the plan, and return for labs? Screen medication possession, food/housing, transport, language, mood/substance use, and caregiver burden.

AdaptGeneric/90-day fills, single-pill combinations, mail pharmacy, home BP upload, interpreter, pharmacist, nutrition and transport support.

AuditDo not let insurance denial, language, disability, geography, sex, race, or cancer become an undocumented reason for lower-intensity prevention.

Vaccination belongs in prevention. Link to current CDC/condition-specific schedules; prioritize influenza, COVID-19, pneumococcal, zoster, hepatitis, and RSV by age/risk.

During pregnancy, prioritize behavioral cessation support. Medication requires individualized obstetric review because pregnancy-specific efficacy and safety evidence is insufficient.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Prevent without obstructing cancer care. Establish baseline risk, anticipate exposure-specific toxicity, treat modifiable risk early, and share hold/resume decisions with oncology/cardio-oncology. “Permissive cardiotoxicity” still requires surveillance and ownership.

Before therapy

one baseline dataset

ClinicalBP · symptomsCVD/HF, exam, tobacco, function, pregnancy, prior therapy.

MetabolicLipids · A1ceGFR + UACR, electrolytes; optimize direct indications.

CardiacECG · echoEcho for high-risk exposure/patient; troponin/NP selectively.

ExposureDrug · RT fieldDose, schedule, prior anthracycline/chest radiation, interactions.

Exposure → prevention focus

monitor early

Exposure	CV signal	Action
VEGF inhibitor / TKI	Early HTN, LV dysfunction, ischemia/thrombosis, QT depending on agent.	Home BP daily in the first VEGFi cycle and after dose increases, then every 2–3 weeks. Reassess BP drugs when VEGFi stops. Choose ACEi/ARB ± a dihydropyridine CCB as indicated and check drug interactions.
BTK inhibitor	HTN, AF, bleeding, ventricular arrhythmia/HF signal.	BP + rhythm surveillance; antithrombotic/interaction review; coordinate agent selection.
Abiraterone · steroids · ADT	HTN, fluid/electrolyte change, diabetes, obesity, dyslipidemia.	BP, K, weight/edema, glucose and lipids; treat CKM risk prospectively.
Anthracycline / HER2	LV dysfunction/HF.	Risk-tier surveillance; optimize BP/CAD/HF therapy. New symptoms/troponin/echo change → cardio-oncology pathway.
ICI	Myocarditis, myositis, conduction disease, arrhythmia; often early.	Chest pain, dyspnea, weakness, ptosis, palpitations/syncope → urgent ECG, troponin, CK and specialist pathway; not routine prevention follow-up.
Chest radiation	Accelerated CAD, valvular, pericardial, myocardial and vascular disease—risk rises with dose and time.	Document dose/field/age; lifelong risk-factor control and exposure/symptom-directed surveillance.

BP, lipids & ownership

coordinate holds

Severe therapy-associated BPFor SBP ≥180 or DBP ≥110, assess acute organ injury and obtain urgent multidisciplinary review. Defer or temporarily withhold culprit therapy until SBP <160 and DBP <100, with a documented oncology/cardio-oncology restart plan.

Lipid therapyContinue indicated therapy unless contraindicated. Cancer alone is not a universal statin indication, but selected high cardiotoxicity-risk patients may merit specialist-directed statin consideration.

InteractionsPravastatin, rosuvastatin, and pitavastatin often have fewer CYP interactions, yet transporter effects and dose caps remain; run the specific drug pair.

SurvivorshipAnnual BP/lipid/CKM/tobacco/activity review; preserve exposure record. New symptoms trigger diagnosis, not screening reassurance.

Surveillance is a dated pathway

risk tier + exposure + trigger

Baseline	Record CVD/HF phenotype, BP/home cuff, ECG, lipids/A1c/eGFR/UACR, prior cardiotoxic exposure, planned agent/dose/field, symptoms, pregnancy and drug interactions.
Early cycles	Use exposure-specific BP, rhythm, ECG/echo and biomarker surveillance; new symptoms or objective change move to the toxicity pathway, not the annual-risk visit.
During therapy	Trend rather than reset: weight/volume, BP, renal/electrolytes, glucose/lipids, rhythm, function and treatment dose. Share any hold threshold and resumption owner.
Treatment transition	Reconcile discontinued/continuing therapies, reverse temporary holds, document cumulative exposure, and transfer the next surveillance date explicitly.
Survivorship	Annual conventional prevention plus exposure- and symptom-directed evaluation; chest radiation, anthracycline/HER2 and vascular/metabolic therapies create different timelines.

Shared decision line: oncology owns cancer efficacy; cardiology/cardio-oncology owns the CV assessment and treatment recommendation; the hold/resume decision is multidisciplinary and documented.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Secondary prevention is phenotype-specific. Close LDL, BP, tobacco, CKM, rehabilitation, and adherence gaps in every patient; then choose antithrombotic and residual-risk layers by CAD, stroke, PAD, bleeding risk, and concurrent anticoagulation.

Core stack

close gaps quickly

Domain	Target / treatment	Boundary
Atherogenic lipids	High-intensity/max tolerated statin; LDL <70 if ASCVD not very high risk; <55 / non-HDL <85 if very high risk. Add ezetimibe then PCSK9-directed therapy by gap.	Do not apply <55 automatically to every ASCVD phenotype; do not wait through serial weak steps after recurrence.
BP	Usually <130/80; ACEi/ARB with albuminuric CKD, diabetes, CAD/HF; β-blocker only for current indication.	Orthostasis, kidney/electrolyte safety, angina/low DBP, frailty.
CKM	SGLT2/GLP-1/finerenone/obesity therapy by proven phenotype; eGFR + UACR.	Do not choose by A1c alone or extrapolate a class outcome to every agent.
Rehabilitation	Cardiac rehab after MI/PCI/CABG; supervised/structured exercise for PAD; stroke rehabilitation; tobacco treatment.	Referral is not completion—confirm attendance and barriers.

Antithrombotic by phenotype

indication + stop date

Chronic CAD · no OAC	Usually single antiplatelet; selected high-ischemic/low-bleeding-risk CAD/PAD may use rivaroxaban 2.5 mg BID + aspirin.
Post-ACS / PCI	DAPT agent and duration by ischemic/bleeding risk, stent/ACS context, and current guideline; document de-escalation/stop date.
Noncardioembolic stroke/TIA	Antiplatelet strategy by mechanism and time window; short DAPT only for eligible early minor stroke/high-risk TIA. OCEANIC-STROKE is a new 2026 result, but indication/regulatory guidance must be followed.
Symptomatic PAD / revascularization	Antiplatelet + structured exercise/foot care; consider vascular-dose rivaroxaban + aspirin when ischemic benefit exceeds bleeding risk.
AF / other OAC indication	Anticoagulant strategy supersedes routine aspirin; shorten combined therapy when possible using the exact coronary/stroke indication.

Selected residual-risk layers

after the foundation

Icosapent ethylREDUCE-IT enrolled TG 135–499. US risk-reduction labeling starts at TG ≥150 with CVD or diabetes + ≥2 CV risk factors on maximal tolerated statin. EPA 2 g BID, with AF/bleeding review.

Colchicine 0.5 mg/dOptional selected stable CAD layer after standard prevention. Avoid severe renal/hepatic impairment and strong CYP3A4/P-gp inhibitors; review CBC/interactions.

PAD foot / limbFoot inspection, pulses, wounds/infection, protective footwear, structured walking, diabetes/tobacco care; urgent pathway for acute limb ischemia or CLTI.

Never stack blindlyAspirin + DAPT + anticoagulation requires a defined indication, owner, duration, gastroprotection/bleeding plan, and stop date.

Secondary-prevention visit close

recurrence exposes open loops

LDL laneCurrent/untreated LDL, risk category, goal, expected combination effect, adherence/access, and recheck date.

Antithrombotic laneExact vascular and OAC indication, agent(s), bleeding risk, gastroprotection, duration, de-escalation and stop date.

BP + CKM laneValidated home average, standing safety, eGFR/UACR, K/volume, diabetes/HF/CKD layers, and next lab.

Recovery laneCardiac/stroke/PAD rehabilitation attendance, activity prescription, tobacco treatment, foot/limb or neurologic safety, function and mood.

Residual-risk laneTG/EPA phenotype, selected stable-CAD colchicine, obesity/OSA, inflammation, and recurrent-event mechanism—only after the core stack.

Ownership laneWho closes each gap, what data return, the next escalation if off goal, and the date—not “follow up with cardiology.”

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

A prescription without a monitoring date is an open loop. Shorten the interval for CKD, older age/frailty, multiple simultaneous changes, abnormal baseline labs, diuretics, interacting drugs, or symptoms.

Therapy monitoring matrix

baseline · first check · later · hold/refer

Change	Baseline	First check	Later	Hold / refer
Statin / nonstatin	Lipids, ALT; CK if indicated.	Lipids 4–12 wk; symptoms.	Every 3–12 mo.	Severe weakness, marked CK, liver injury; pregnancy review.
ACEi / ARB	K, creatinine/eGFR, volume.	~1–2 wk if high risk; no later than 2–4 wk.	After titration; periodic.	Significant hyperK/AKI, symptomatic hypotension, pregnancy.
Thiazide / loop	Na, K, creatinine, volume, uric acid context.	1–2 wk.	After titration; periodic.	Major electrolyte/volume issue, gout complication.
Spironolactone / finerenone	K, eGFR, interactions.	Spironolactone: K within 1 wk after start/titration. Finerenone: K/eGFR at 4 wk. Earlier checks if high risk.	About q4 mo or risk/label-based.	K/eGFR threshold, interacting strong inhibitor, acute illness.
SGLT2 inhibitor	eGFR, volume, DKA/infection risk.	Early clinical/volume check.	Kidney/volume, sick-day review.	Fasting/surgery, acute illness, suspected DKA.
GLP-1 / obesity drug	Weight/waist, BP/pulse, GI/gallbladder/pancreas, retinopathy, pregnancy.	Each titration.	At least q3 mo once stable.	Persistent vomiting/dehydration, pancreatitis concern, unsafe/ineffective therapy.
Antithrombotic	Indication, CBC, renal/liver function, bleeding/drug interactions.	Early adherence/bleeding check.	Each visit; renal interval by drug/risk.	Major bleeding, unexplained anemia, unsafe stacking.

Visit cadence

ownership by date

~1 monthBP medication start/intensification; home-log review; symptoms, adherence, labs, dose step.

4–12 weeksLipid start/change; compare expected vs observed response, adherence, access, adverse effects; add therapy if off goal.

Each titrationWeight/GLP-1 therapy; nutrition, hydration, GI symptoms, muscle/function, hypoglycemia-prone drugs, affordability.

Every stable visitMedication possession, refill gap, home BP upload, tobacco, activity, sleep, mood, access, shared decision, stop dates.

One-line close Today I started/changed ____ · expected effect ____ · warning symptoms ____ · labs on ____ · home data by ____ · dose decision on ____ · next visit ____ · owner ____

Escalate instead of repeating. Persistent uncontrolled BP, LDL far above goal, recurrent events, severe TG/FH, progressive CKD/albuminuria, medication intolerance, or complex oncology/pregnancy interactions warrants specialist/pharmacist/team escalation.

Abnormal first check → named response

do not file and forget

Effect smaller than expected	Confirm possession, dose, timing, technique and interacting causes; resolve access/adherence, then intensify rather than repeating the same plan.
K/creatinine/Na change	Assess volume, illness, NSAIDs/supplements and interacting drugs; compare with baseline and the agent-specific threshold before hold, dose change or recheck.
Orthostasis / volume loss	Standing vitals, intake/GI loss, diuretic and BP burden; protect organ-benefit therapy when possible by removing the least necessary contributor.
GI intolerance / weight loss	Slow escalation, nutrition/hydration/constipation plan, review lean-mass risk and hypoglycemia-prone drugs; urgent symptoms exit the routine pathway.
Bleeding / anemia	Assess severity/source, CBC/renal/liver function and all antithrombotics/NSAIDs; preserve only therapies with a current indication and explicit duration.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Practice-changing trials — checked October 17, 2026. Match phenotype, comparator, absolute benefit, harms and background therapy. Follow-up is median unless labeled mean.

Blood pressure & lipids

peer-reviewed outcomes

Trial	Population / comparison	Result	Boundary
SPRINT	9,361 · high risk without diabetes/prior stroke. SBP <120 vs <140.	1.65 vs 2.19/100 person-y, HR 0.75. Mortality HR 0.73. 3.26 y.	Standardized BP. More hypotension, electrolyte abnormality and AKI.
ESPRIT	11,255 · high-risk HTN including diabetes/prior stroke. SBP <120 vs <140.	9.7% vs 11.1%, HR 0.88. 3.4 y.	Broader than SPRINT. More syncope.
BPROAD	12,821 · T2D + elevated CV risk. SBP <120 vs <140.	1.65 vs 2.09/100 person-y, HR 0.79. 4.2 y.	Selected diabetes. More symptomatic hypotension and hyperkalemia.
CLEAR Outcomes	13,970 · statin-intolerant ASCVD/high risk. Bempedoic acid.	11.7% vs 13.3%, HR 0.87. 40.6 mo.	More gout/cholelithiasis. Retain a tolerated statin.
VESALIUS-CV	12,257 · atherosclerosis/high-risk diabetes without prior MI/stroke, LDL ≥90. Evolocumab.	5-y MACE-3 estimates 6.2% vs 8.0%, HR 0.75. Follow-up 4.6 y.	Kaplan–Meier estimates in selected high-risk adults.
REDUCE-IT	8,179 · statin-treated ASCVD or diabetes + risk, TG 135–499. Icosapent ethyl 2 g BID.	17.2% vs 22.0%, HR 0.75. 4.9 y.	More AF/flutter hospitalization. Serious bleeding 2.7% vs 2.1% (P=0.06).

Inflammation, HIV & antithrombotics

indication matters

REPRIEVE	7,769 · ART-treated HIV, low/moderate risk. Pitavastatin 4 mg.	4.81 vs 7.32 MACE/1,000 person-y, HR 0.65. 5.1 y.	Check ART interactions. Modest muscle/diabetes excess.
LoDoCo2 / CLEAR SYNERGY	Stable CAD (N=5,522) vs acute MI (N=7,062). Colchicine 0.5 mg daily.	Stable CAD HR 0.69 over 28.6 mo. Acute MI HR 0.99 over 3 y.	Context-specific. Routine acute-MI use not supported.
COMPASS	27,395 across 3 arms. Stable CAD/PAD. Rivaroxaban 2.5 mg BID + aspirin vs aspirin.	MACE 4.1% vs 5.4%, HR 0.76. Major bleed 3.1% vs 1.9%. Mean 23 mo.	High ischemic / low bleeding risk only.
OCEANIC-STROKE	12,327 · recent noncardioembolic stroke/high-risk TIA. Asundexian on antiplatelet therapy.	Ischemic stroke 6.2% vs 8.4%, HR 0.74. Major bleed 1.9% vs 1.7%, HR 1.10 (95% CI 0.85–1.44).	Stroke phenotype only. Does not establish AF use or a class effect.

Evidence labels Peer-reviewed outcome benefit ≠ regulatory indication ≠ guideline recommendation. Confirm all three when the result is new.

Translate a trial in four passes

effect size is not the whole answer

Population matchEntry criteria, baseline event risk, excluded phenotypes, run-in, background therapy, setting, follow-up and discontinuation.

EffectAbsolute event rates, time horizon, HR/RR with confidence interval, competing outcomes, components and recurrent versus first events.

HarmsAbsolute adverse-event excess, discontinuation, bleeding/infection/metabolic injury, monitoring burden and interaction with comorbidity.

ImplementationRegulatory indication, guideline status, dose/product, access, feasibility, patient goal and whether the comparator still reflects current care.

Write the bedside translation

one sentence, all boundaries

Benefit	“In patients like ____ on ____ background therapy, ____ changed ____ from ____ to ____ over ____.”
Harm	“The main tradeoff was ____ (absolute excess ____), plus monitoring/access burden ____.”
Decision	“This supports ____ product/dose for ____ indication. It does not establish ____.”

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

CKM evidence — checked October 17, 2026. Separate placebo superiority from active-comparator noninferiority, kidney composites from MACE, and weight/biomarker change from dedicated event reduction. Follow-up is median unless labeled mean.

Diabetes, kidney & obesity

match the phenotype

Trial	Population	Result	Boundary
SELECT	17,604 · BMI ≥27 + CVD without diabetes. Semaglutide 2.4 mg weekly.	MACE 6.5% vs 8.0%, HR 0.80. Mean 39.8 mo.	Secondary prevention. Permanent AE discontinuation 16.6% vs 8.2%.
FLOW	3,533 · T2D + albuminuric CKD. Semaglutide 1 mg weekly.	Kidney/CV-death HR 0.76, MACE HR 0.82, all-cause death HR 0.80. 3.4 y.	Use CKD foundation. Not all CKD phenotypes enrolled.
SOUL	9,650 · T2D + ASCVD and/or CKD. Oral semaglutide.	MACE 12.0% vs 13.8%, HR 0.86. 49.5 mo.	Direct oral GLP-1 outcome evidence in high-risk T2D.
SURPASS-CVOT	13,299 randomized, 13,165 modified ITT. T2D + ASCVD. Tirzepatide vs dulaglutide.	MACE 12.2% vs 13.1%, HR 0.92 (95.3% CI 0.83–1.01).	Noninferiority met. Superiority to dulaglutide not established (P=0.09).
DAPA-CKD	4,304 · albuminuric CKD ± diabetes. Dapagliflozin.	Kidney/CV-death composite 9.2% vs 14.5%, HR 0.61. 2.4 y.	Benefit with and without diabetes. This is not MACE.
EMPA-KIDNEY	6,609 · broad CKD ± diabetes. Empagliflozin.	Kidney progression/CV death 13.1% vs 16.9%, HR 0.72. 2.0 y.	Broader eGFR/albuminuria spectrum.
FIDELITY	13,026 · T2D + CKD. Finerenone pooled analysis.	CV composite 12.7% vs 14.4%, HR 0.86. 3.0 y.	Albuminuric CKD on RAAS blockade. Monitor K/eGFR.

Negative boundaries & implementation

what not to promise

ASPREE / ASCEND / ARRIVE	Primary-prevention aspirin has no broad net benefit. Small vascular benefit may be offset by bleeding.	No routine aspirin. Individualize exceptional use.
DAPA-MI / EMPACT-MI	DAPA-MI excluded prior diabetes/chronic HF. EMPACT-MI enrolled increased HF risk after MI, with or without diabetes.	Neither established universal post-MI hard-outcome benefit. Treat separate HF/CKD/T2D indications.
SECURE	2,499 after MI. Aspirin/ramipril/atorvastatin polypill vs usual care.	9.5% vs 12.7%, HR 0.76 over 36 mo. Strategy improved outcomes and adherence.

Five-check translation Match population · compare absolute benefit · quantify harms · identify comparator/background therapy · solve feasibility/access. Biomarker lowering alone is not event reduction.

Make the five checks visible

before adding a layer

1 · PopulationSame disease stage, albuminuria/eGFR, diabetes/CVD/HF status, BMI, age, exclusions and baseline absolute risk?

2 · ComparatorPlacebo, usual care or active drug? Was contemporary RAAS/SGLT2/statin/antithrombotic therapy present and balanced?

3 · EndpointMACE, kidney failure/CV death composite, HF events, weight, A1c or biomarker? First event or recurrent events?

4 · Benefit + harmAbsolute difference and duration, confidence interval, discontinuation and the adverse event that matters to this patient.

5 · Use nowExact agent/product/dose, FDA indication, guideline position, monitoring, interaction, access and patient goal.

Hard boundaryNoninferiority is not superiority. A class cousin is not the tested molecule. A kidney or weight endpoint is not automatically MACE.

Common inference errors

stop before extrapolation

Surrogate → event	LDL, BP, UACR, A1c, weight or inflammatory-marker improvement may justify an approved surrogate indication. It does not create an untested event claim.
Composite → every component	A positive composite does not prove each component. Inspect event counts, hierarchy, multiplicity and whether one component drove the result.
Selected → universal	Enrichment, adherence run-in, specialist follow-up and narrow phenotype can raise benefit and lower apparent implementation burden.
Negative → never useful	A neutral outcome trial can still define a boundary. Treat the separate HF/CKD/T2D/weight indication when it is independently proven.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Registry and evidence check — October 17, 2026. Primary completion (PC) dates are estimates unless labeled actual. Registry results, sponsor toplines and published papers are separate evidence states.

Registry status & recent outcomes

status is not an outcome

Trial · NCT	Population / N	Status / PC	Evidence / outcome question
Lp(a)HORIZONNCT04023552 · pelacarsen	CVD + Lp(a) ≥70 mg/dL. N=8,323.	Completed Jul 16, 2026 actual	Sponsor topline Sep 4: primary expanded-MACE endpoint not met. Full event/safety data pending.
ZEUSNCT05021835 · ziltivekimab	ASCVD + CKD + hsCRP ≥2 mg/L. N=6,385.	Completed Jun 9, 2026 actual	Sponsor topline Jul 31: MACE HR 0.99 (95% CI 0.88–1.11), more serious infections. Full report pending.
ORION-4NCT03705234 · inclisiran	Prior MI, ischemic stroke or PAD. N=16,124.	Active, not recruiting Oct 2026 est.	Does twice-yearly PCSK9 siRNA reduce MACE?
PREVAILNCT05202509 · obicetrapib	ASCVD with LDL inadequately controlled. N=9,541.	Active, not recruiting Nov 2026 est.	CETP inhibition and CV death/MI/stroke/revascularization. Date is not a promised readout.
HERMESNCT05636176 · ziltivekimab	HFmrEF/HFpEF + hsCRP ≥2 mg/L. N=4,874.	Terminated Sep 3, 2026 actual	No registry results. Registry stop wording does not establish an efficacy conclusion.
REDEFINE 3NCT05669755 · CagriSema	Age ≥55, BMI ≥25, CVD ± T2D. N=7,101.	Active, not recruiting Sep 2027 est.	CV outcomes for semaglutide + cagrilintide.
VICTORION-2PNCT05030428 · inclisiran	CVD with LDL ≥70 mg/dL. N=17,004.	Active, not recruiting May 2027 est.	Independent secondary-prevention MACE test.
SURMOUNT-MMONCT05556512 · tirzepatide	BMI ≥27 + CVD or enriched primary-prevention risk. N=15,374.	Active, not recruiting Oct 2027 est.	Death, atherothrombotic and HF outcomes in selected high-risk adults.

Do now

Use approved/outcomes-proven therapies in their current indication. Control LDL, BP, CKM risk, tobacco, activity, sleep and access.

Wait for

Peer-reviewed events, absolute harms/benefits, subgroup consistency, regulatory indication and implementation guidance.

Near-term status ledger: evidence-gated

completed or available ≠ MACE benefit

State / trial	Question	Current boundary
COMPLETED · SYNCHRONIZE-CVOTNCT06077864 · Jun 1, 2026 actual	Survodutide CV safety. BMI ≥27 + CVD or ≥2 risk factors, or BMI ≥30 + CVD/CKD or ≥2 factors. N=5,531.	No registry results. Sponsor Oct 1 expected results later in 2026. Weight efficacy does not answer CV outcomes.
COMPLETED · LIBREXIA-ACSNCT05754957 · Feb 6, 2026 actual	Milvexian + antiplatelet therapy after ACS. N=14,194. Median follow-up 12.2 mo.	Published neutral result: MACE 5.4% vs 5.1%, HR 1.05 (95% CI 0.91–1.21).
ACTIVE, NOT RECRUITING · LIBREXIA-STROKENCT05702034 · Oct 15, 2026 est.	Milvexian after ischemic stroke/high-risk TIA. N=12,523.	No registry results. OCEANIC-STROKE does not establish a factor-XIa class effect.
AVAILABLE · Enlicitide	FDA-approved oral PCSK9 for LDL lowering.	CORALreef event trial pending.
AVAILABLE · Inclisiran	FDA-approved LDL lowering.	ORION-4 and VICTORION event trials pending.
AVAILABLE · Orforglipron	FDA-approved oral obesity therapy.	No dedicated MACE-reduction claim.
AVAILABLE · Baxdrostat	FDA-approved add-on BP therapy.	Label lacks controlled CV-event reduction trials.

Interpretation: no ClinicalTrials.gov results does not mean no published results. Topline announcements require full event and safety data. A neutral result for one agent does not settle the entire mechanism.

START · RISK · LIPIDS · BP · CKM · PEOPLE · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Outcomes pipeline — checked October 17, 2026. Dates are estimated primary completion, not promised results. Separate approved indications from investigational use, and clinical events from biomarker change.

Active, not recruiting

outcomes pending

Trial	Population / intervention	Primary completion	Clinical question
OCEAN(a)-OutcomesNCT05581303	Prior MI or PCI + risk factor, Lp(a) ≥200 nmol/L. Olpasiran. N=7,297.	Mar 2028	Time to first CHD death, MI or urgent coronary revascularization.
EASi-KIDNEYNCT06531824	Progressive CKD ± T2D. Aldosterone-synthase inhibition + empagliflozin. N=8,371.	Dec 2026	Registry active, not recruiting. No results. Sep 15 sponsor update body not verified in this review.
TRIUMPH-OutcomesNCT06383390	BMI ≥27 + ASCVD and/or CKD ± T2D. retatrutide. N≈10,000.	Feb 2029	CV death/MI/stroke/HF and kidney outcomes.
ACCLAIM-Lp(a)NCT06292013	Lp(a) ≥175 nmol/L + ASCVD or high first-event risk. Lepodisiran. N≈17,300.	Mar 2029	Time to first MACE-4 after randomization.
VICTORION-1 PREVENTNCT05739383	High-risk adults without prior major event. inclisiran. N=14,012.	Apr 2029	Does inclisiran prevent first major ASCVD events?
CORALreef OutcomesNCT06008756	High CV risk. Oral enlicitide. N≈14,550.	Nov 2029	MACE-plus includes limb ischemia/amputation and urgent arterial revascularization.

Recruiting

mechanism to hard outcomes

MARITIME-CVNCT07037433	ASCVD + overweight/obesity. Maridebart cafraglutide. N≈12,800.	Jun 2028	MACE-3 and expanded five-component CV endpoint, with long-term safety.
ZENITHNCT07181109	High CV risk + uncontrolled HTN on ≥2 drugs including a diuretic. Zilebesiran q6mo. N≈11,000.	Sep 2030	Hard-outcome test of RNAi BP lowering.

Do not prescribe a mechanism. Lp(a), IL-6, aldosterone synthase, RNAi BP, triple incretin and oral PCSK9 biology may be compelling. Practice changes after patient-important outcomes, safety, approval, and implementation—not a biomarker slide.

Mechanism watchlist

biomarker promise ≠ event proof

State / item	Question or current use	Boundary
WATCH · ApoC-III / ANGPTL3	Severe TG/chylomicronemia and rare lipid phenotypes.	Olezarsen reduces TG and acute-pancreatitis risk in severe HTG (≥500 mg/dL). No general ASCVD indication.
WATCH · Renal denervation	Durable BP lowering and medication-burden strategy.	Sham-controlled BP lowering is not proof of fewer MI, stroke, HF or death.
WATCH · Inflammation	IL-6 inhibition, colchicine implementation, precision inflammatory phenotypes.	Infection/non-CV harm and disease context can erase biomarker enthusiasm.

Cutting edge, not over the edge. Use approved/guideline-supported options with their exact evidence tier, phenotype, monitoring, interactions, cost, and patient goal. Never turn registry status, a press release, biomarker lowering, weight loss, noninferiority, or class analogy into an unearned MACE claim.

START · RISK · LIPIDS · BP · CKM · PEOPLE · RISK CONTINUUM · ONCOLOGY · ASCVD · FOLLOW-UP · EVIDENCE

Severe plaque can raise risk without changing the evidence base. A prior clinical event or a separately established clinical ASCVD phenotype can make the patient truly secondary prevention. Severe subclinical plaque can instead create secondary-prevention-level risk while the patient remains primary prevention by event history: risk-equivalent, not evidence-equivalent.

Which lane is this?

disease · plaque · risk factors

Lane	What puts the patient there?	What follows?
Actually established disease	Prior MI/ACS, coronary revascularization, atherosclerotic ischemic stroke/TIA, symptomatic PAD, or a separately diagnosed chronic/obstructive coronary disease phenotype.	Use disease- and phenotype-specific secondary-prevention guidance. The age rule against initiating primary-prevention aspirin is not the correct framework.
Severe subclinical plaque	No clinical event, but CAC >300 (particularly ≥400)—especially extensive/diffuse plaque or CAC ≥1,000. CAC is direct evidence of coronary atherosclerosis, not merely another risk factor.	LDL/BP/tobacco/diabetes intensity may resemble secondary prevention. Aspirin, DAPT, low-dose rivaroxaban, stress testing, and angiography do not travel as a bundle.
High-risk primary prevention	LDL ≥190/FH, diabetes, CKD, smoking, high Lp(a), strong family history, or multiple uncontrolled risk factors without established clinical ASCVD.	Treat each direct indication aggressively; high predicted risk alone does not create an antiplatelet indication.

Colorized scanning electron micrograph of carotid plaque, with orange calcification among green collagen layers. — **Calcium is part of plaque.** This carotid-plaque micrograph shows calcification in orange and collagen in green. It is tissue microscopy, not a coronary CT or an example from which to calculate CAC. The image illustrates mineralized plaque, not lumen narrowing or ischemia.
E.Aikawa, 2013 · CC BY-SA 4.0 · image unchanged.

Why high CAC changes the conversation

plaque burden is a risk multiplier

Observed riskIn the observational CONFIRM registry, patients without prior ASCVD and CAC >300 had comparable observed MACE rates to those with established ASCVD; equivalence was not proven. That supports secondary-prevention-level risk framing, not proof that every secondary-prevention drug works the same way.

Treatment intensityThe 2026 lipid guideline labels CAC 300–999 severe subclinical atherosclerosis; use plaque burden to intensify durable risk-factor treatment and close the LDL gap.

What CAC cannot answerCalcium does not define lumen severity, ischemia, plaque vulnerability, or bleeding risk. The 2023 chronic coronary disease guideline excludes asymptomatic high-CAC patients without prior ASCVD events from its scope. Do not order functional/anatomic testing solely to complete a high-CAC cascade in an asymptomatic patient.

The key separationLipid-lowering benefit scales with atherosclerotic risk; aspirin benefit must still exceed hemorrhagic harm. A high calcium score cannot neutralize bleeding risk.

Aspirin balance sheet

discussion, not a score-triggered prescription

Factors that favor a discussion	Factors that argue against initiation
CAC ≥100, with the strongest modeled signal at ≥400; CAC >300 plus high total ischemic risk; long benefit horizon; controlled BP; no bleeding history or interacting therapy; patient preference after absolute-risk discussion; prevention-specialist input.	Age >70 itself; prior GI/intracranial bleeding or peptic ulcer; anemia, thrombocytopenia/coagulopathy, CKD, uncontrolled HTN, frailty/falls; anticoagulant, regular NSAID, or steroid use; limited life expectancy / an insufficient benefit horizon. High bleeding risk overrides CAC.

Know the evidence boundary. Contemporary MESA net-benefit estimates were modeling—not a randomized CAC-guided aspirin trial—and excluded adults ≥70 and those at high bleeding risk. USPSTF advises against initiating at ≥60; ACC/AHA and the 2026 ACC statement advise against routine use >70 while preserving individualized clinical judgment.

Translate the case: age >70 + CAC >300, no event

reasonable clinicians can weigh this differently

The case for aspirinSevere measured plaque and observed risk approaching stable ASCVD make the possible absolute ischemic benefit more credible than in low-risk primary prevention. The 2019 guideline explicitly leaves room to discuss select older patients with significant CAC.

The case againstASPREE found no statistically significant reduction in cardiovascular disease and more major hemorrhage in healthy older adults; it did not select by CAC. The CAC net-benefit model excluded this age group, so benefit remains extrapolated.

Operational closeFirst confirm no hidden clinical ASCVD; maximize lipid, BP, tobacco, diabetes, exercise, and weight treatment. The default after age 70 is not to initiate primary-prevention aspirin. Benefit is unproven; any exception is an evidence-limited individual discussion after bleeding-risk review and prevention input, not a CAC-supported recommendation.

Do not cross the lanesDo not stop separately indicated secondary-prevention aspirin merely because the patient turns 70. Do not start primary-prevention aspirin solely because CAC crosses 300.